Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis

REFERENCES

1. 1.↵
   1. Gossec L,
   2. Baraliakos X,
   3. Kerschbaumer A, et al.

   EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Coates LC,
   2. Soriano ER,
   3. Corp N, et al.

   Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465-79.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Runarsdottir EE,
   2. Gunnarsdottir AI,
   3. Love TJ,
   4. Gunnarsson PS,
   5. Gudbjornsson B, ICEBIO

   . The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials. Clin Exp Rheumatol 2018;36:1068-73.

   OpenUrlPubMed
4. 4.↵
   1. Ureyen SB,
   2. Ivory C,
   3. Kalyoncu U,
   4. Karsh J,
   5. Aydin SZ.

   What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatol Adv Pract 2018;2:rkx019.
5. 5.↵
   1. Vandendorpe AS,
   2. De Vlam K,
   3. Lories R.

   Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments. RMD Open 2019;5:e000779.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Gossec L,
   2. Siebert S,
   3. Bergmans P, et al.

   Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis 2023;82:496-506.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Tricco AC,
   2. Lillie E,
   3. Zarin W, et al.

   PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467-73.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Munn Z,
   2. Peters MDJ,
   3. Stern C,
   4. Tufanaru C,
   5. McArthur A,
   6. Aromataris E.

   Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 2018;18:143.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. PROSPERO

   . International prospective register of systematic reviews. [Internet. Accessed October 29, 2024.] Available from: https://www.crd.york.ac.uk/prospero/
10. 10.↵
    1. Mease PJ,
    2. McInnes IB,
    3. Kirkham B, et al.

    Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-39.

    OpenUrlCrossRefPubMed
11. 11.
    1. McInnes IB,
    2. Mease PJ,
    3. Kirkham B, et al.

    Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.

    OpenUrlCrossRefPubMed
12. 12.
    1. Kavanaugh A,
    2. Husni ME,
    3. Harrison DD, et al.

    Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol 2017;69:2151-61.

    OpenUrlCrossRefPubMed
13. 13.
    1. Mease PJ,
    2. Gottlieb AB,
    3. Van Der Heijde D, et al.

    Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 2017;76:1550-8.

    OpenUrlAbstract/FREE Full Text
14. 14.
    1. Mease PJ,
    2. Van Der Heijde D,
    3. Ritchlin CT, et al; SPIRIT-P1 Study Group

    . Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017;76:79-87.

    OpenUrlAbstract/FREE Full Text
15. 15.
    1. Nash P,
    2. Kirkham B,
    3. Okada M, et al; SPIRIT-P2 Study Group

    . Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. The Lancet 2017;389:2317-27.

    OpenUrl
16. 16.
    1. Mease P,
    2. van der Heijde D,
    3. Landewé R, et al.

    Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77:890-7.

    OpenUrlAbstract/FREE Full Text
17. 17.
    1. Mease PJ,
    2. Gladman DD,
    3. Collier DH, et al.

    Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled Phase III trial. Arthritis Rheumatol 2019;71:1112-24.

    OpenUrlCrossRefPubMed
18. 18.
    1. Deodhar A,
    2. Helliwell PS,
    3. Boehncke WH, et al.

    Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1115-25.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Mease PJ,
    2. Rahman P,
    3. Gottlieb AB, et al; DISCOVER-2 Study Group

    . Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1126-36.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Viechtbauer W.

    Conducting meta-analyses in R with the metafor package. J Stat Softw 2010;36:1-48.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Desthieux C,
    2. Granger B,
    3. Balanescu AR, et al.

    Determinants of patient-physician discordance in global assessment in psoriatic arthritis: a multicenter European study. Arthritis Care Res 2017;69:1606-11.

    OpenUrlCrossRef
22. 22.↵
    1. Michelsen B,
    2. Kristianslund EK,
    3. Hammer HB, et al.

    Discordance between tender and swollen joint count as well as patient’s and evaluator’s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 2017;76:708-11.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Kasiem FR,
    2. Kok MR,
    3. Luime JJ, et al; CICERO

    . The burden of psoriasis in patients with early psoriatic arthritis. Rheumatology 2022;61:1570-8.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Palsson O,
    2. Love TJ,
    3. Gunnarsdottir AI, et al.

    Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open 2019;5:e000984.

    OpenUrlAbstract/FREE Full Text